Cargando…

Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study

INTRODUCTION: To compare all-cause and rheumatoid arthritis (RA)-related healthcare costs and resource use in patients with RA who do not achieve remission versus those who achieve remission, using clinical practice data. METHODS: Data were derived from Optum electronic health records linked to clai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergman, Martin, Zhou, Lili, Patel, Pankaj, Sawant, Ruta, Clewell, Jerry, Tundia, Namita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107161/ https://www.ncbi.nlm.nih.gov/pubmed/33837497 http://dx.doi.org/10.1007/s12325-021-01730-w

Ejemplares similares

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
por: Bergman, Martin, et al.
Publicado: (2021)

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2020)

Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2021)

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review
por: Ostor, Andrew J., et al.
Publicado: (2021)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis
por: Aoki, Tadashi, et al.
Publicado: (2020)

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
por: Bergman, Martin, et al.
Publicado: (2022)

Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry
por: Bergman, Martin J., et al.
Publicado: (2022)

Remission in Rheumatoid Arthritis
por: Shammas, Rania M., et al.
Publicado: (2010)

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE
por: Strand, Vibeke, et al.
Publicado: (2021)

Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission
por: Hammer, Hilde Berner, et al.
Publicado: (2021)

A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2023)

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
por: Strand, Vibeke, et al.
Publicado: (2020)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
por: Fakhfakh, Rym, et al.
Publicado: (2021)

Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review
por: Gul, Hanna, et al.
Publicado: (2021)

Achieving comprehensive remission or low disease activity in rheumatoid patients and its impact on workability – Saudi Rheumatoid Arthritis Registry
por: Almoallim, Hani, et al.
Publicado: (2019)

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment
por: Miwa, Yusuke, et al.
Publicado: (2017)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
por: Paul, Stéphane, et al.
Publicado: (2020)

Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission
por: Kameda, Hideto, et al.
Publicado: (2021)

Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission
por: Ben Abdelghani, Kawther, et al.
Publicado: (2022)

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
por: Vermeer, Marloes, et al.
Publicado: (2013)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Patient’s perspective of sustained remission in rheumatoid arthritis
por: Contreras-Yáñez, Irazú, et al.
Publicado: (2017)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis
por: Parantainen, J., et al.
Publicado: (2022)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Correction: Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Publicado: (2016)

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
por: Hashimoto, Motomu, et al.
Publicado: (2018)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Sustained rheumatoid arthritis remission is uncommon in clinical practice
por: Prince, Femke HM, et al.
Publicado: (2012)

Defining and characterizing sustained remission in patients with rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2017)

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Molecular remission at T cell level in patients with rheumatoid arthritis
por: Inamo, Jun, et al.
Publicado: (2021)

Sustained Remission in Rheumatoid Arthritis: Time to Withdraw Treatment?
por: Sungur, Can M.
Publicado: (2021)

Rheumatoid Arthritis: Defining Clinical and Ultrasound Deep Remission
por: Hèctor, Corominas, et al.
Publicado: (2020)

Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis
por: Thorne, Jennifer E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6g8cn0vj540t663m1ro1bis1qh